retatrutide phase 3 trial dosing schedule First data, a Triumph of Science! retatrutide dosing schedule clinical trial

Understanding what to expect and how to manage each symptom turns a potentially miserable first few weeks into a manageable adjustment period

Both options present side effects, predominantly gastrointestinal issues, which necessitate careful consideration and discussion with healthcare providers

These approaches are broadly consistent with guidance used for managing fatigue associated with other GLP-1 receptor agonists, as reflected in NHS and NICE resources for weight management pharmacotherapy (including NICE TA875 on semaglutide for weight management)

2022 DOI: 10.1016/S0140-6736(22)02033-5 PMID: 36354040 Read on PubMed The Lancet Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Rosenstock J, Frias J, Jastreboff AM, et al